Weight Changes in Patients Using Nurtec ODT: Patient-Reported Outcomes from a Real-World Survey
Weight Changes Associated with Rimegepant
DOI:
https://doi.org/10.66381/jod.2025.004Keywords:
Nurtec ODT, rimegepant, CGRP antagonist, weight change, migraineAbstract
Background: Nurtec ODT (rimegepant) is a calcitonin gene-related peptide (CGRP) receptor antagonist approved for acute and preventive treatment of migraine in adults. Clinical trials have primarily focused on efficacy and headache-related adverse events; however, anecdotal evidence and patient feedback suggest a potential association between Nurtec ODT and weight changes.
Objectives: To assess real-world, patient-reported experiences of weight change following initiation of Nurtec ODT and to determine whether patients attributed these changes to the medication.
Methods: A cross-sectional online survey was conducted among Nurtec ODT users. Respondents reported weight changes over a three-month period and provided self- assessment regarding the extent of change and whether they attributed the change to Nurtec ODT.
Results: Of the 32 respondents, 29 (91%) reported a change in weight after starting Nurtec ODT. Weight gain of 5–10 lbs was reported by 55%, while 19% reported gaining more than 10 lbs. Weight loss was reported by 12%, and 10% noted no significant change. Among those with weight changes, 86% believed Nurtec ODT was the primary cause.
Conclusion: A considerable proportion of Nurtec ODT users reported moderate weight gain within three months of use, with most attributing the change to the medication. Although weight changes are not listed as adverse events in clinical trial data, these real-world findings underscore the need for pharmacovigilance and further clinical investigation.
Downloads
References
1. Steiner, T.J., Stovner, L.J. Global epidemiology of migraine and its implications for public health and health policy. Nat Rev Neurol 19, 109–117 (2023). DOI: 10.1038/s41582-022-00763-1
2. Jahromi, S. R., Martami, F., Morad Soltani, K., & Togha, M. (2023). Migraine and obesity: what is the real direction of their association? Expert Review of Neurotherapeutics, 23(1), 75–84. DOI: 10.1080/14737175.2023.2173575
3. Ghiami, H., Parsapour, M., Khalilzadeh, S. et al. Efficacy and safety of calcium channel blockers in migraine management; a systematic review. Naunyn-Schmiedeberg's Arch Pharmacol 398, 16401–16414 (2025). DOI: 10.1007/s00210-025-04422-2
4. Croop R, Lipton RB, Kudrow D, Stock DA, Kamen L, Conway CM, et al. Rimegepant, an oral calcitonin gene–related peptide receptor antagonist, for migraine. N Engl J Med. 2019;381(2):142–9. DOI: 10.1056/NEJMoa1811090
5. Biohaven Pharmaceuticals. Nurtec ODT Prescribing Information [Internet]. New Haven (CT): Biohaven Pharmaceuticals; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212728s000lbl.pdf
6. Edvinsson L. The CGRP pathway in migraine as a viable target for therapies. Headache. 2018;58(Suppl 1):33–47. https://doi.org/10.1111/head.13305
7. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Rimegepant. [Updated 2025 Jan 12]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK572432/
8. Kristoffersen ES, Børte S, Hagen K, Zwart JA. Migraine, obesity and body fat distribution – a population-based study. Cephalalgia. 2020;40(4):369–78. DOI: 10.1186/s10194-020-01163-w
9. Peterlin BL, Rapoport AM, Kurth T. Migraine and obesity: epidemiology, mechanisms, and implications. Headache: The Journal of Head and Face Pain. 2010 Apr;50(4):631-48. DOI: 10.1111/j.1526-4610.2009.01554.x
Downloads
Published
Data Availability Statement
The datasets generated and analyzed during the current study are not publicly available due to participant confidentiality and the anonymous nature of the survey responses. De-identified data may be made available from the corresponding author on reasonable request for academic or research purposes.
License
Copyright (c) 2025 Journal of Diabesity
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles published in the Journal of Diabesity (JOD) are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0).
What this means:
Under the CC BY 4.0 license, authors retain copyright of their work, while allowing others to:
-
Share — Copy and redistribute the material in any medium or format
-
Adapt — Remix, transform, and build upon the material for any purpose, even commercially
Conditions:
Users must provide appropriate attribution to the original author(s) and source, including:
-
The article title
-
Author(s) name(s)
-
Journal name (Journal of Diabesity)
-
DOI or link to the original article
-
An indication if changes were made
There is no restriction on commercial use or derivative works, as long as proper attribution is given.
Full License Text:
https://creativecommons.org/licenses/by/4.0/
✍️ Author Rights:
-
Authors retain copyright and grant JOD the right of first publication.
-
Authors may archive the published version in institutional repositories, personal websites, or other platforms with proper citation.
